MedTrace Logo

Ultra Rapid GEnome Sequencing

NCT06555731 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4

Last updated 2024-12-18

No results posted yet for this study

Summary

Next-generation sequencing (NGS) has revolutionized the field of genomics, allowing the detection of genetic abnormalities for diagnostic or therapeutic purposes. Turnaround times for exome or genome sequencing results have decreased to an average of 3 to 6 months.

An increasing number of diagnostic and therapeutic fields are benefiting from the advancements in ultra-rapid sequencing. In some situations, a shorter turnaround time may be useful for making therapeutic and/or interventional management decisions.

This study aims to explore the feasibility of very rapid whole-genome sequencing, ultra-rapid genome sequencing (URGES) in 72 hours, that could benefit patients with cancer or rare diseases.

Conditions

  • Whole Genome Sequencing

Interventions

GENETIC

Ultra rapid genome sequencing

DNA extraction from blood sample and whole genome sequencing

Sponsors & Collaborators

  • CMC Ambroise Paré

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-08
Primary Completion
2024-10-12
Completion
2024-10-12

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06555731 on ClinicalTrials.gov